Countrywide Spread of Community- and Hospital-Acquired Extended-Spectrum β-Lactamase (CTX-M-15)-Producing <i>Enterobacteriaceae</i> in Lebanon
-
- Carole Moubareck
- Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris 5-René Descartes, Paris, France
-
- Ziad Daoud
- Saint George Hospital, and University of Balamand, Beirut, Lebanon
-
- Noha I. Hakimé
- Saint George Hospital, and University of Balamand, Beirut, Lebanon
-
- Monzer Hamzé
- Lebanese University, Beirut, and Nini Hospital, Tripoli, Lebanon
-
- Nicole Mangeney
- Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris 5-René Descartes, Paris, France
-
- Hiam Matta
- Arz Hospital, Al Metn, Lebanon
-
- Jacques E. Mokhbat
- Rizk Hospital, Beirut, Lebanon
-
- Raymond Rohban
- Saint Joseph Hospital, Beirut, Lebanon
-
- Dolla Karam Sarkis
- Hôtel Dieu de France Hospital, Beirut, Lebanon
-
- Florence Doucet-Populaire
- Laboratoire de Microbiologie, Faculté des Sciences Pharmaceutiques et Biologiques, Université Paris 5-René Descartes, Paris, France
Description
<jats:title>ABSTRACT</jats:title> <jats:p> A prospective study was carried out to assess the extent of carriage of extended-spectrum β-lactamase (ESBL)-producing <jats:italic>Enterobacteriaceae</jats:italic> at both hospital and community levels in Lebanon. A total of 1,442 fecal samples were collected from hospital-based patients and 58 from health care workers of six Lebanese tertiary care general hospitals located in different areas of Lebanon between January and March 2003. A total of 382 fecal samples were also collected from healthy subjects between April and June 2003. The samples analysis led to the identification of 118 strains as ESBL producers based on the synergistic effects between clavulanate and selected β-lactams (ceftazidime and cefotaxime). These strains were isolated from 72 subjects: 61 patients, 2 health care workers, and 9 healthy subjects. One representative strain per subject was selected, and a total of 72 nonduplicate ESBL producers, including a high majority of <jats:italic>Escherichia coli</jats:italic> ( <jats:italic>n</jats:italic> = 56), <jats:italic>Klebsiella pneumoniae</jats:italic> ( <jats:italic>n</jats:italic> = 9), <jats:italic>Enterobacter cloacae</jats:italic> ( <jats:italic>n</jats:italic> = 6), and <jats:italic>Citrobacter freundii</jats:italic> ( <jats:italic>n</jats:italic> = 1), were characterized. The molecular analysis revealed that the majority of the strains (83%) express CTX-M-15 ESBL (pI 8.6). SHV-5a ESBL (pI 8.2) was produced by 18% of the strains. DNA macrorestriction analysis of ESBL-producing <jats:italic>E. coli</jats:italic> presented 38 different genotypes, revealing the absence of clonal link among these strains. In addition to the fact that the present study highlights the emergence and the countrywide dissemination of CTX-M-15-producing <jats:italic>E. coli</jats:italic> in Lebanon, it represents the first report of an SHV-5a-producing <jats:italic>C. freundii</jats:italic> . </jats:p>
Journal
-
- Journal of Clinical Microbiology
-
Journal of Clinical Microbiology 43 (7), 3309-3313, 2005-07
American Society for Microbiology
- Tweet
Details 詳細情報について
-
- CRID
- 1361418519469179264
-
- ISSN
- 1098660X
- 00951137
- http://id.crossref.org/issn/00951137
-
- Data Source
-
- Crossref